FFM

Fairmount Funds Management Portfolio holdings

AUM $1.11B
1-Year Est. Return 120.99%
This Quarter Est. Return
1 Year Est. Return
+120.99%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$772M
AUM Growth
+$127M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
18
New
Increased
Reduced
Closed

Top Buys

1
+$32.2M
2
+$22.4M
3
+$18.6M
4
SRRK icon
Scholar Rock
SRRK
+$15.9M
5
ELVN icon
Enliven Therapeutics
ELVN
+$10.2M

Top Sells

1
+$10.2M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$5.52B
$89M 11.53%
2,048,647
AXSM icon
2
Axsome Therapeutics
AXSM
$8.94B
$85.1M 11.02%
815,176
ELVN icon
3
Enliven Therapeutics
ELVN
$1.59B
$74.5M 9.65%
3,711,444
+508,646
SRRK icon
4
Scholar Rock
SRRK
$4.59B
$64.6M 8.37%
1,824,031
+450,000
SYRE icon
5
Spyre Therapeutics
SYRE
$2.58B
$60.2M 7.79%
4,018,101
NUVL icon
6
Nuvalent
NUVL
$8.1B
$55.5M 7.19%
727,563
DNTH icon
7
Dianthus Therapeutics
DNTH
$1.89B
$50.4M 6.53%
2,707,191
+6,500
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$2.99B
$49.1M 6.36%
1,772,839
+670,591
VRDN icon
9
Viridian Therapeutics
VRDN
$3.17B
$48.4M 6.27%
3,459,913
+14,100
COGT icon
10
Cogent Biosciences
COGT
$5.98B
$44.7M 5.79%
6,225,641
ORKA
11
Oruka Therapeutics
ORKA
$1.62B
$37.8M 4.9%
3,371,922
JBIO
12
Jade Biosciences
JBIO
$725M
$32.2M 4.17%
+3,220,368
CBIO
13
Crescent Biopharma
CBIO
$411M
$22.4M 2.9%
+1,387,866
ATXS icon
14
Astria Therapeutics
ATXS
$712M
$19.1M 2.47%
3,554,129
ZBIO
15
Zenas BioPharma
ZBIO
$1.08B
$18.3M 2.38%
1,892,806
IKT icon
16
Inhibikase Therapeutics
IKT
$203M
$11.9M 1.55%
6,125,000
CTMX icon
17
CytomX Therapeutics
CTMX
$913M
$8.85M 1.15%
+3,896,582
BCAX
18
Bicara Therapeutics
BCAX
$918M
– –
-784,170